Print
Email
Print Edition StoriesMonday, January 4, 2010
Hanke to head BioVex commercialization
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Galen Moore: Hiring trends and opportunities
BioVex Inc., a Woburn-based developer of cancer and infectious disease drugs and vaccines, has named Tim Hanke as its vice president of commercial operations. He will be responsible for moving the company’s OncoVEX GM-CSF product to commercialization.
Hanke joins BioVex having previously served as director of global commercial operations at Genta Inc., a biopharmaceutical firm also dedicated to cancer treatment. Prior to Genta, he worked for Chiron Biopharmaceuticals and Berlex Laboratories Inc.
OncoVEX GM-CSF is a cancer treatment, which BioVex calls an “oncolytic vaccine,” made to destroy cancer cells without harming healthy cells. The treatment is currently in a Special Protocol Assessment (SPA) Phase 3 study for melanoma, and the FDA has approved it for a Phase 3 study for head and neck cancer, also under SPA.
More about BioVex
In November, BioVex capped its Series F round of funding with $30 million to add to its first $40 million of the round announced in March. The new funding saw participation from new investors including Sectoral Asset Management and Ysios Capital Partners, and the round was co-led by Morningside Venture, Ventech and MVM Life Science Partners.
BioVex has its headquarters in Woburn and maintains its research and development facility in Oxford, England.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
